Treatment with Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ELd) in patients with relapsed/refractory multiple myeloma (RRMM) continued to show effectiveness in the Phase 3…
Patients with newly diagnosed multiple myeloma benefit significantly from a combination of Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone, followed by Ninlaro maintenance therapy, according…
Doctors told Don Wright he had five years to live when he was diagnosed with multiple myeloma in 2003. Instead of resigning himself to this…
The U.S. Food and Drug Administration (FDA) has accepted a supplemental biologics license application (sBLA) seeking to expand the currently approved indication of Xgeva…
The U.S. Federal Drug Administration has approved a combination of the immunotherapies Darzalex (daratumumab), Pomalyst (pomalidomide) and dexamethasone as a multiple myeloma treatment, according to…
Dragonfly Therapeutics and Celgene have teamed up to develop therapies for multiple myeloma and other blood cancers. The partners will use Dragonfly’s TriNKET immunotherapy…
Massachusetts–based Karyopharm Therapeutics announced that the first patient was dosed in its pivotal BOSTON Phase 3 clinical trial…
John Theurer Cancer Center and MedStar Georgetown University Hospital have announced the completion of the 100th blood stem cell transplant since its joint…
Merck has suspended patient enrollment in two Phase 3 clinical trials, KEYNOTE-183 and KEYNOTE-185, testing Keytruda (pembrolizumab) in combination with other therapies in patients…
Caris Life Sciences is collaborating with the National Cancer Institute (NCI) to identify patients eligible to participate in the Phase 2 NCI-MATCH (Molecular Analysis for Therapy Choice) study,…